tbuckley/cabot-search huggingface dataset:
Association Between Androgen Deprivation Therapy and Risk of Dementia
Authors: Kevin T. Nead, Greg Gaskin, Cariad Chester, Samuel Swisher-McClure, Nicholas J. Leeper, Nigam H. Shah
Journal: JAMA Oncology (2016)

<h3>Importance</h3> A growing body of evidence supports a link between androgen deprivation therapy (ADT) and cognitive dysfunction, including Alzheimer disease. However, it is currently unknown whether ADT may contribute to the risk of dementia more broadly. <h3>Objective</h3> To use an informatics approach to examine the association of ADT as a treatment for prostate cancer with the subsequent development of dementia (eg, senile dementia, vascular dementia, frontotemporal dementia, and Alzheimer dementia). <h3>Design, Setting, and Participants</h3> In this cohort study, a text-processing method was used to analyze electronic medical record data from an academic medical center from 1994 to 2013, with a median follow-up of 3.4 years (interquartile range, 1.0-7.2 years). We identified 9455 individuals with prostate cancer who were 18 years or older at diagnosis with data recorded in the electronic health record and follow-up after diagnosis. We excluded 183 patients with a previous diagnosis of dementia. Our final cohort comprised 9272 individuals with prostate cancer, including 1826 men (19.7%) who received ADT. <h3>Main Outcomes and Measures</h3> We tested the effect of ADT on the risk of dementia using propensity score–matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. <h3>Results</h3> Among 9272 men with prostate cancer (mean [SD] age, 66.9 [10.9] years; 5450 [58.8%] white), there was a statistically significant association between use of ADT and risk of dementia (hazard ratio, 2.17; 95% CI, 1.58-2.99;<i>P</i> &lt; .001). In sensitivity analyses, results were similar when excluding patients with Alzheimer disease (hazard ratio, 2.32; 95% CI, 1.73-3.12;<i>P</i> &lt; .001). The absolute increased risk of developing dementia among those who received ADT was 4.4% at 5 years (7.9% among those who received ADT vs 3.5% in those who did not receive ADT). Analyses stratified by duration of ADT found that individuals with at least 12 months of ADT use had the greatest absolute increased risk of dementia (hazard ratio, 2.36; 95% CI, 1.64-3.38;<i>P</i> &lt; .001). Kaplan-Meier analysis demonstrated that ADT users 70 years or older had the lowest cumulative probability of remaining dementia free (log-rank<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> Androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia. This finding should be further evaluated in prospective studies.
Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology
Authors: Christian Dittrich, Michael P. Kosty, Svetlana Jezdic, Doug Pyle, Rossana Berardi, Jonas Bergh, Nagi S. El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne
Journal: Journal of Clinical Oncology (2016)
Do patients with initially resected metastatic GIST benefit from ‘adjuvant‘ imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial
Authors: B. N. Bui, A. Le Cesne, I. Ray-Coquard, F. Duffaud, M. Rios, A. Adenis, E. Bonpas, D. Perol, P. Berthaud, J. Blay
Journal: Journal of Clinical Oncology (2006)

9501 Background: Metastatic GIST patients (pts) without residual disease after surgical resection are considered as at very high risk of relapse (VHR) but the impact of imatinib (IM) treatment while in CR (‘adjuvant‘ IM) is still debated. Preliminary data for such patients included in the modified BFR14 (continuation vs discontinuation of IM after 3 years of treatment) are presented. Methods: Characteristics and outcome of patients with VHR at inclusion and treated with IM were analyzed. Pts initially allocated to the discontinuation of BFR14 after 1 year of IM were excluded from this analysis. Results: Out of 265 pts with advanced disease, 96 metastatic, completely resected, GIST pts (52 males and 44 females) were included in the trial with a median age of 61 years (range 28 to 87). Primary resected sites were gastric and small bowel in 40% and 42% of cases respectively. Site of dissemination in synchronously resected (R0/R1 resections) metastases was liver only (45%), peritoneum only (15%) and liver plus peritoneum (22%). The median duration of ‘adjuvant‘ IM in the whole population of 96 pts was 13 months (range 0 to 34.3). At time of analysis (december 2005), 34 pts have progressed and 13 pts died of their disease. The median PFS was 25 months (CI 95%: 20.3 ; 34.4) and the 2 year-OS was 80.7% (CI 95%: 68.6 ; 92.8). Conclusions: These results confirm the poor prognosis of VHR GIST pts and justify IM treatment of initially resected metastatic GIST like other metastatic diseases. Optimal duration of IM has to be validated in a prospective way and these pts are considered in BFR 14 trial Updated results will be presented at the meeting. This work is supported by research funding from Novartis Pharma. [Table: see text]
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC
Authors: Roelof Willemze, Stefan Suciu, Franco Mandelli, Giovanna Meloni, Boris Labar, Stijn J.M. Halkes, Petra Muus, Martin Mistrik, Giorgina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik Selleslag, Francois Lefrere, Domenico Magro, Giuseppe Leone, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Lorella Melillo, Dominique Bron, Georges Fillet, Jose E. Guimaraes, Sergio Amadori, Paola Fazi, Matthias Karrasch, Marco Vignetti, Theo de Witte, Jean-Pierre Marie
Journal: Blood (2011)
Curcumin Induces Apoptosis by Inhibiting the Expression of IAPs in Human Precursor B-Acute Lymphoblastic Leukemic (PreB-ALL) Cells.
Authors: Azhar R. Hussain, Abdul K. Siraj, Pulicat S. Manogaran, Khawla S. Al-Kuraya, Shahab Uddin
Journal: Blood (2005)
Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia
Authors: Lai N Chan, Daniel Braas, Christian Hurtz, Seyedmehdi Shojaee, Behzad Kharabi Masouleh, Huimin Geng, Thomas Ernst, Andreas Hochhaus, Thomas Graeber, Markus Muschen
Journal: Blood (2014)
限定された心臓細胞集団による胚性幹(ES)細胞工学組織シートは心筋梗塞後の機能を回復させる
Authors: Masumoto Hidetoshi, Shimizu Tatsuya, Ikeda Tadashi, Okano Teruo, Sakata Ryuzo, Yamashita Jun
Journal: Circulation (2011)
PTU-148 A large prospective audit of morbidity and mortality associated with feeding gastrostomies in the community: Abstract PTU-148 Table 1
Authors: E Clarke, V Chudleigh, N Pitts, A Latchford, S Lewis
Journal: Gut (2015)

<h3>Introduction</h3> Morbidity after 30 days and morbidity after 1 year from gastrostomy placement is poorly characterised as patients are discharged into the community. We prospectively recorded morbidity and mortality associated with gastrostomy placement over a five year period. <h3>Method</h3> Community dietitians regularly reviewed all patients with a gastrostomy after hospital discharge, prospectively recording morbidity and mortality between 2008–2012. In addition hospital databases and case notes were examined. Recorded morbidity included insertion site infection, leakage, over granulation, haemorrhage and buried bumper. <h3>Results</h3> There were no deaths and few complications directly related to gastrostomy insertion in 350 patients. We collected a total of 571 years of gastrostomy data. Mortality within 10 days was predominantly from a respiratory cause. 30 day, 3 and 21 month cumulative mortality (and morbidity) were 8% (2%), 16% (10%) and 35% (15%) respectively. 38% of patients required treatment for an insertion site infection with 70% of these having further infections. Overall there was a site infection every 2.1 years a gastrostomy was <i>in situ</i>. Complications such as buried bumpers, persistent fistulas and overgranulation were rare. Few gastrostomies required replacement (11%). <h3>Conclusion</h3> This is the first prospective study of morbidity and mortality in a large number of patients undergoing gastrostomy placement over an extended period of time. We have demonstrated reassuringly low rates of gastrostomy-associated morbidity and mortality. There was no direct mortality. The greatest morbidity resulted from gastrostomy-site infection. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Dennis MS, Lewis SC, Warlow C, FOOD Trial Collaboration. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet 2005:365(9461):764–772 Johnston SD, <i>et al</i>. Death after PEG: results of the national confidential enquiry into patient outcome and death. Gastrointest Endosc. 2008;68(2):223–227 Mitchell SL, <i>et al</i>. The risk factors and impact on survival of feeding tube placement in nursing home residents with severe cognitive impairment. Arch Intern Med. 1997;157(3):337–332 Sheehan JJ. Percutaneous endoscopic gastrostomy. Irish Med J. 2003;96(9) Westaby D, <i>et al</i>. The provision of a percutaneously placed enteral tube feeding service. Gut 2010;59:1592–1605 Wilcox CM, McClave SA. To peg or not to peg. Clin Gastroenterol Hepatol. 2013;11(11):1451–1452
Screening, Evaluation, and Treatment of Peripheral Arterial Disease
Authors: Christopher L. Skelly, Adam S. Cifu
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-320 3D-Cardiac-gated Contrast-enhanced Multidetector Computed Tomography (3D-CCCT) Analysis Of The Native Mitral Valve
Authors: Renick D. Lee, Aileen Lomarda, None Bothaina abdulshakour, Bermillon S. Faderan, Swee Yaw Tan, Nicolas Foin, Jia-Lin Soon
Journal: Journal of the American College of Cardiology (2015)
Involvement of Altered PML/RARalpha and RARbeta Expression in Delayed Restoration of Retinoic Acid Sensitivity in UF-1, an Acute Promyelocytic Leukemia Cell Line Carrying a Patient-Derived Mutant PML/RARalpha(Arg611Trp).
Authors: Yoshiyuki Hoshi, Masue Imaizumi, Kazuie Iinuma
Journal: Blood (2004)
The Pattern of Immunoglobulin Variable Genes Indicates That Most Post-Transplant Lymphoproliferative Disorders Derive from B-Cells That Have Failed the Germinal Center Reaction.
Authors: Daniela Capello, Michaela Cerri, Eva Berra, Davide Rossi, Enrica Morra, Giuliana Muti, Marco Paulli, Gianluca Gaidano
Journal: Blood (2004)
Prediagnosis Body Mass Index and Risk of Secondary Primary Cancer in Male Cancer Survivors: A Large Cohort Study
Authors: Sang Min Park, Young Ho Yun, Young Ae Kim, Minkyung Jo, Young-Joo Won, Joung Hwan Back, Eun-Sook Lee
Journal: Journal of Clinical Oncology (2016)

Purpose Male cancer survivors have a higher risk of cancer than the general population, which might be caused by an increased prevalence of obesity or susceptibility to obesity-related carcinogenesis. We assessed the effects of obesity before the diagnosis of a first cancer on the development of secondary primary cancers (SPCs). Methods The study population consisted of 239,615 Korean male cancer survivors between January 2003 and December 2010. Incident SPCs were assessed throughout follow-up until December 2011. Cox proportional hazards models were used to calculate the hazard ratios of SPCs associated with prediagnosis body mass index (BMI), which were compared with those of first cancers in all cohort participants. Results After 1,614,583 person-years of follow-up, we observed 4,799 patients with SPC. The age-standardized incidence rate of cancer in cancer survivors was 1.1 times higher than that of the general population. We found positive linear trends between prediagnosis BMI and risk of all-combined, colorectal, liver, lymphoma, biliary tract, kidney, and obesity-related SPCs. The magnitude of the BMI-SPC risk association in male cancer survivors was stronger than that for first cancers in the general population, whereas the mean BMI was similar in both groups. In the severely obese category (BMI ≥ 30 kg/m 2 ), the adjusted hazard ratios for SPCs among cancer survivors (1.41; 95% CI, 1.15 to 1.74) were significantly higher than those for first cancers among all cohort participants (1.12; 95% CI, 1.09 to 1.16; P heterogeneity &lt; .01). Conclusion Prediagnosis obesity is a risk factor for overall and individual SPCs, and the strength of the BMI-cancer association is slightly stronger in male cancer survivors than in the general population.
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
Authors: Nathan Fowler, Jeff Porte Sharman, Sonali M Smith, Thomas Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Joseph Buggy, David Loury, Ahmed Hamdy, Ranjana Advani
Journal: Blood (2010)
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.
Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon J. S. Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela E. Matei, Anitra Fielding, Stuart Spencer, Philip Rowe, Elizabeth S. Lowe, Ursula A. Matulonis
Journal: Journal of Clinical Oncology (2016)

5501 Background: In a phase II study (NCT00753545, Study 19), maintenance monotherapy with the EU/US-approved PARP inhibitor olaparib significantly improved PFS, and times to first and second subsequent therapy or death (TFST and TSST), vs placebo in PSR SOC pts. Pts with a BRCA1/2 mutation (BRCAm) derived the greatest benefit from olaparib. Analyses after a data cut-off (DCO) on Nov 26, 2012 did not show a significant OS improvement with olaparib in the full analysis set (FAS) (58% maturity; HR 0.88, 95% CI 0.64–1.21, P =0.44) or BRCAm subgroup (52% maturity; HR 0.73, 95% CI 0.45–1.17, P= 0.19) (Ledermann et al, Lancet Oncol 2014). We report updated OS, evaluated after 77% of pts had died (DCO: Sep 30, 2015). Methods: Pts received olaparib (400 mg bid, capsules) or placebo after response to platinum-based therapy. BRCAm status was known for 254/265 pts (96%) from germline or tumor tests. Results: Maintenance olaparib gave pts an OS advantage vs placebo; analyses suggest that the results seen in the FAS may have been driven by the BRCAm group. Investigations into the contribution of pts who were non-BRCAm buthomologous recombination repair deficient are ongoing. In the FAS, 5-yr survival was 29.2% and 20.4% in the olaparib and placebo arms, respectively (36.9% and 24.3% in BRCAm pts). At the 2015 DCO, 15 pts remained on olaparib (BRCAm, n = 8) and 1 on placebo (BRCAm, n = 1). 18/136 FAS pts (13.2%) received olaparib for > 5 yrs (by subgroup: 11/74 BRCAm pts [14.9%]; 7/62 non-BRCAm pts [11.3%]). There was no change to the safety profile and no new cases of MDS/AML were reported since the 2012 DCO. Conclusions: There is an OS advantage for pts in Study 19 receiving maintenance olaparib after response to platinum therapy. Long-term treatment with maintenance olaparib was observed.This analysis supports prior Study 19 data in pts with BRCAm PSR SOC showing a significant PFS benefit and delay to TFST and TSST with olaparib. Clinical trial information: NCT00753545. FAS (77% maturity) BRCAm (70% maturity) Olaparib n = 136 Placebo n = 129 Olaparib n = 74 Placebo n = 62 Events, n (%) 94 (70) 109 (84) 47 (64) 48 (77) Median OS, mo 29.8 27.8 34.9 30.2 HR (95% CI) 0.73 (0.55–0.96) 0.62 (0.41–0.94)
Quality of health information about depression on internet
Authors: A. Tomlin
Journal: BMJ (2001)

Editor—Griffiths and Christensen evaluated the quality of web based information on the treatment of depression.1 Although they have tried to scrutinise the quality of a select group of websites, there are shortcomings in their methods that may have affected their findings.

Griffiths and Christensen used just one search engine (DirectHit) and one meta-search engine (MetaCrawler), which limited the comprehensiveness of their search. Although the popularity of search engines changes rapidly, we question the choice of DirectHit over more often used engines such as AltaVista or Google.2 Therefore, it is difficult to justify the assumption of Griffiths and Christensen that their search method provided the best available approximation to a list of depression sites.

We also question the strategy of using the single search term of “depression,” given that over 44% of internet users search using multiple keywords.3 The extreme narrowness of using a single keyword search was summed up eloquently by Brian Pinkerton, the founder of MetaCrawler, when he said: “Imagine walking up to a librarian and saying, ‘travel.’ They're going to look at you with a blank face.”4

Griffiths and Christensen attempt to assess the quality of information found by comparison with a guideline of the Agency for Health Care Policy and Research (AHCPR) guideline. Readers should be aware that tools, such as DISCERN (www.discern.org.uk), are readily available for appraising the quality of patient information. Furthermore, although the AHCPR guidelines were developed using an evidence based method, they were published in 1993 and may not necessarily reflect recent advances, alternative treatments, or local practice.

Smarter search engines such as SumSearch (http://sumsearch.uthscsa.edu/) try to refine and guide users through the literature, yet a global initiative from the World Health Organization may provide further direction for users. The WHO has proposed the creation of “.health” as a new internet top level domain to afford some measure of protection for internet users by identifying the holder of the domain name as one who adheres to known standards.5 While the feasibility of “dot health” is being debated, national initiatives, such as the National Electronic Library for Health (www.nelh.nhs.uk) are striving to bring together high quality information for patients and health professionals. One of the initial examples of which is information on depression that can be found at http://cebmh.com/depression.html.

Until initiatives such as dot health or high quality web searching tools become available, the onus will remain with users to search effectively and appraise the quality of the sites retrieved.
Extracellular Matrix Proteolysis by MT1-MMP Contributes to Influenza-Related Tissue Damage and Mortality
Authors: Dalit Talmi-Frank, Zeev Altboum, Inna Solomonov, Yael Udi, Diego Adhemar Jaitin, Mordehay Klepfish, Eyal David, Alina Zhuravlev, Hadas Keren-Shaul, Deborah R. Winter, Irit Gat-Viks, Michal Mandelboim, Tamar Ziv, Ido Amit, Irit Sagi
Journal: Cell Host & Microbe (2016)
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
Authors: Nuh N. Rahbari, Dmitriy Kedrin, Joao Incio, Hao Liu, William W. Ho, Hadi T. Nia, Christina M. Edrich, Keehoon Jung, Julien Daubriac, Ivy Chen, Takahiro Heishi, John D. Martin, Yuhui Huang, Nir Maimon, Christoph Reissfelder, Jurgen Weitz, Yves Boucher, Jeffrey W. Clark, Alan J. Grodzinsky, Dan G. Duda, Rakesh K. Jain, Dai Fukumura
Journal: Science Translational Medicine (2016)

Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).
Authors: Auayporn P. Nademanee, Jasmine M. Zain, Joycelynne Palmer, Nicole Tsai, Neil Martin Kogut, Amrita Krishnan, Leslie Popplewell, Roberto Rodriguez, Eileen Patricia Smith, Stephen J. Forman
Journal: Blood (2006)
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network randomized prospective phase II trial
Authors: D. S. Thompson, J. D. Hainsworth, L. H. Morrissey, J. B. Erland, H. A. Burris, G. Joseph, S. W. Corso, E. Spremulli, F. A. Greco
Journal: Journal of Clinical Oncology (2004)

7205 Background: Platinum plus etoposide chemotherapy is currently standard for patients (pts) with extensive stage small cell lung cancer. Nonplatinum doublets of active newer drugs may be superior. Methods: The purpose of this randomized phase II trial was to compare the toxicity, response rates, and progression-free survival (PFS) of platinum/etoposide-based chemotherapy to paclitaxel plus topotecan. Between December 1999 and June 2003, 120 pts with extensive stage small cell lung cancer were randomized to receive either Arm A (60 pts): paclitaxel 200mg/m2 day 1, carboplatin AUC 6 day 1, oral etoposide 50mg alternating with 100mg for 10 consecutive days for 4 cycles (repeated every 3 weeks) versus Arm B (60 pts): paclitaxel 175mg/m2 day 1, and topotecan 1.5mg/m2 days 1, 2, and 3, for 4 cycles (repeated every 3 weeks). Eligibility required no prior chemotherapy, ECOG performance status (PS) 0–1, and normal organ function. Results: Pts were evenly matched with respect to PS, visceral metastases, number of metastatic sites, and gender. There were 68 men and 52 women. Grade 3/4 neutropenia/thrombocytopenia: Arm A - 20 pts (33%)/6 pts (10%); Arm B - 27 pts (45%)/14 pts (23%). Nonhematologic toxicity was similar in both arms. Overall response rates were 77% (38 pts) in Arm A and 49% (25 pts) in Arm B (p=0.03) with 13% (8 pts) with complete responses in Arm A and 6.5% (4 pts) in Arm B (p=0.12), respectively. The median PFS in Arm A was 7.4 months versus 5.5 months for Arm B (p=0.0043). Progression-free survival at 12 months and 18 months was 15% and 8% in Arm A and 8% and 0% in Arm B, respectively. Median survival in Arm A was 10.6 months versus 9.1 months in Arm B (p=0.2581). The 12-month and 18-month survival was 38% and 20% in Arm A and 30% and 13% in Arm B, respectively. Conclusions: The overall toxicity profile, response rate, and PFS of paclitaxel/carboplatin/etoposide (Arm A) is superior to the nonplatinum doublet of paclitaxel plus topotecan (Arm B). Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb; GlaxoSmithKline